These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25467150)

  • 1. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
    Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
    Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
    Gao Y; Ye DY; Zhou WC; Chu Y
    Eur J Med Chem; 2017 Jul; 135():370-381. PubMed ID: 28460311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
    Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.
    Bidon-Chanal A; Fuertes A; Alonso D; Pérez DI; Martínez A; Luque FJ; Medina M
    Eur J Med Chem; 2013 Feb; 60():479-89. PubMed ID: 23354070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
    Arfeen M; Patel R; Khan T; Bharatam PV
    J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
    Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC
    Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
    Mohammad MK; Al-Masri IM; Taha MO; Al-Ghussein MA; Alkhatib HS; Najjar S; Bustanji Y
    Eur J Pharmacol; 2008 Apr; 584(1):185-91. PubMed ID: 18295757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS; Balaji B; Rani P; Ramanathan M
    J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
    Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
    J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of small molecules that inhibit GSK-3beta through virtual screening.
    Kang NS; Lee GN; Kim CH; Bae MA; Kim I; Cho YS
    Bioorg Med Chem Lett; 2009 Jan; 19(2):533-7. PubMed ID: 19081248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor.
    Licht-Murava A; Plotkin B; Eisenstein M; Eldar-Finkelman H
    J Mol Biol; 2011 Apr; 408(2):366-78. PubMed ID: 21354422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glycogen synthase kinase-3beta improves tolerance to ischemia in hypertrophied hearts.
    Barillas R; Friehs I; Cao-Danh H; Martinez JF; del Nido PJ
    Ann Thorac Surg; 2007 Jul; 84(1):126-33. PubMed ID: 17588398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site.
    Rippin I; Khazanov N; Shirley Ben Joseph ; Kudinov T; Berent E; Arciniegas Ruiz SM; Marciano D; Levy L; Gruzman A; Senderowitz H; Eldar-Finkelman H
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.
    La Pietra V; La Regina G; Coluccia A; Famiglini V; Pelliccia S; Plotkin B; Eldar-Finkelman H; Brancale A; Ballatore C; Crowe A; Brunden KR; Marinelli L; Novellino E; Silvestri R
    J Med Chem; 2013 Dec; 56(24):10066-78. PubMed ID: 24295046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation.
    Mohammad M; Al-Masri IM; Issa A; Al-Ghussein MA; Fararjeh M; Alkhatib H; Taha MO; Bustanji Y
    J Enzyme Inhib Med Chem; 2013 Aug; 28(4):690-4. PubMed ID: 22512725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation.
    Motawi TM; Bustanji Y; El-Maraghy SA; Taha MO; Al Ghussein MA
    J Biochem Mol Toxicol; 2013 Sep; 27(9):425-36. PubMed ID: 23784744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation.
    Bustanji Y; Taha MO; Almasri IM; Al-Ghussein MA; Mohammad MK; Alkhatib HS
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):771-8. PubMed ID: 18720192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.